Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers (Retraction in: Anesthesiology (2010) 112:4 (1056-1057))

Anesthesiology

Volumn 99, Issue 2, 2003, Pages 303-313

  Fechner, Jörg ^a   Ihmsen, Harald ^a   Hatterscheid, Dirk ^a   Schiessl, Christine ^a   Vornov, James J ^b   Burak, Eric ^b   Schwilden, Helmut ^a   Schüttler, Jürgen ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AQUAVAN; FOSPHENYTOIN SODIUM; GPI 15715; PRODRUG; PROPOFOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BURNING SENSATION; COMPARTMENT MODEL; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; INJECTION PAIN; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SKIN TINGLING;

ADULT; ANESTHESIA, INTRAVENOUS; ANESTHETICS, INTRAVENOUS; AREA UNDER CURVE; BLOOD PRESSURE; CONSCIOUSNESS; HALF-LIFE; HEART RATE; HUMANS; MALE; MODELS, BIOLOGICAL; PRODRUGS; PROPOFOL; RESPIRATORY MECHANICS;

EID: 0041343200     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200308000-00012     Document Type: Article

References (25)

1. Bryson HM, Fulton BR, Faulds D: Propofol: An update of its use in anaesthesia and conscious sedation. Drugs 1995; 50:513-59
2. Albrecht S, Ihmsen H, Suchodolski K, Frenkel C, Schuttler J: [Analgosedation in intensive care: A quantitative, EEG-based trial with propofol 1% and 2%]. Anaesthesist 1999; 48:794-801
3. Lindholm M: Critically ill patients and fat emulsions. Minerva Anestesiol 1992; 58:875-79
4. Kelbel I, Koch T, Weber A, Schiefer HG, van Ackern K, Neuhof H: Alterations of bacterial clearance induced by propofol. Acta Anaesthesiol Scand 1999; 43:71-76
5. Nakane M, Iwama H: A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate. Br J Anaesth 1999; 83:397-404
6. Doursout MF, Joseph PM, Liang YY, Hartley CJ, Chelly JE: Role of propofol and its solvent, intralipid, in nitric oxide-induced peripheral vasodilatation in dogs. Br J Anaesth 2002; 89:492-98
7. Ririe DG, Lundell JC, Neville MJ: Direct effects of propofol on myocardial and vascular tissue from mature and immature rats. J Cardiothorac Vasc Anesth 2001; 15:745-9
8. Plummer GF: Improved method for the determination of propofol in blood by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 421:171-76
9. Hughes MA, Glass PS, Jacobs JR: Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. ANESTHESIOLOGY 1992; 76:334-41
10. Gepts E, Camu F, Cockshott ID, Douglas EJ: Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg 1987; 66:1256-63
11. Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, Siegel JL: Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: Study with intravenous midazolam. J Clin Psychopharmacol 1990; 10:244-51
12. Kirkpatrick T, Cockshott ID, Douglas EJ, Nimmo WS: Pharmacokinetics of propofol (Diprivan) in elderly patients. Br J Anaesth 1988; 60:146-50
13. Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL, Youngs EJ: The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. ANESTHESIOLOGY 1998; 88:1170-82
14. Schuttler J, Ihmsen H: Population pharmacokinetics of propofol: A multicenter study. ANESTHESIOLOGY 2000; 92:727-38
15. Tackley RM, Lewis GT, Prys-Roberts C, Boaden RW, Dixon J, Harvey JT: Computer controlled infusion of propofol. Br J Anaesth 1989; 62:46-53
16. Dutta S, Ebling WF: Formulation-dependent brain and lung distribution kinetics of propofol in rats. ANESTHESIOLOGY 1998; 89:678-85
17. Dutta S, Ebling WF: Formulation-dependent pharmacokinetics and pharmacodynamics of propofol in rats. J Pharm Pharmacol 1998; 50:37-42
18. Wakeling HG, Zimmerman JB, Howell S, Glass PS: Targeting effect compartment or central compartment concentration of propofol: What predicts loss of consciousness? ANESTHESIOLOGY 1999; 90:92-7
19. Kazama T, Ikeda K, Morita K, Kikura M, Doi M, Ikeda T, Kurita T, Nakajima Y: Comparison of the effect-site k(eO)s of propofol for blood pressure and EEG bispectral index in elderly and younger patients. ANESTHESIOLOGY 1999; 90:1517-27
20. Schuttler J, Stoeckel H, Schwilden H: Pharmacokinetic and pharmacodynamic modelling of propofol ("Diprivan") in volunteers and surgical patients. Postgrad Med J 1985; 61:53-54
21. Forrest FC, Tooley MA, Saunders PR, Prys-Roberts C: Propofol infusion and the suppression of consciousness: The EEG and dose requirements. Br J Anaesth 1994; 72:35-41
22. Smith C, McEwan AI, Jhaveri R, Wilkinson M, Goodman D, Smith LR, Canada AT, Glass PS: The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision. ANESTHESIOLOGY 1994; 81:820-8; discussion 26A
23. Shafer A, Doze VA, Shafer SL, White PF: Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ANESTHESIOLOGY 1988; 69:348-56
24. Struys MM, De Smet T, Versichelen LF, Van De Velde S, Van den Broecke R, Mortier EP: Comparison of closed-loop controlled administration of propofol using Bispectral Index as the controlled variable versus "standard practice" controlled administration. ANESTHESIOLOGY 2001; 95:6-17
25. Schuttler J: Pharmakokinetik und -dynamik des intravenösen Anaesthetikums Propofol (Disoprivan). Berlin, Heidelberg, New York, Springer, 1990